Title page

Proteomic and metabolomic signatures associated with the immune response in healthy individuals immunized with an inactivated SARS-CoV-2 vaccine

Yi Wang,^{1,#,*} Xiaoxia Wang,^{2,#} Laurence Don Wai Luu,^{3,#} Shaojin Chen², Fu Jin,¹ Shufang Wang,⁴ Xiaolan Huang,¹ Licheng Wang,² Xiaocui Zhou,² Xi Chen,² Xiaodai Cui,¹ Jieqiong Li,^{5,*} Jun Tai,^{6,*} and Xiong Zhu^{2,*}

¹ Experimental Research Center, Capital Institute of Pediatrics, Beijing, 100020, P.R. China

² Central & Clinical Laboratory of Sanya People's Hospital, Sanya, Hainan 572000, P. R. China.

³ School of Biotechnology and Biomolecular Science, University of New South Wales, Sydney, Australia

⁴ Nursing department of Sanya People's Hospital, Sanya, Hainan 572000, P. R. China.

⁵ Department of Respiratory Disease, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 10045, P. R. China

⁶ Department of Otolaryngology, Head and Neck Surgery, Children's Hospital Capital Institute of Pediatrics, Beijing 100020, P. R. China.

These authors contributed equally

* Correspondence:

Dr. Yi Wang, wildwolf0101@163.com (Handling the correspondence)

Prof. Jieqiong Li, jieqiongli2010@163.com

Prof. Jun Tai, trenttj@163.com

Prof. Xiong Zhu, zhuxiong6@163.com

30 **Summery**

31 CoronaVac (Sinovac), an inactivated vaccine for SARS-CoV-2, has been widely used
 32 for immunization. However, analysis of the underlying molecular mechanisms driving
 33 CoronaVac-induced immunity is still limited. Here, we applied a systems biology
 34 approach to understand the mechanisms behind the adaptive immune response to
 35 CoronaVac in a cohort of 50 volunteers immunized with 2 doses of CoronaVac.
 36 Vaccination with CoronaVac led to an integrated immune response that included
 37 several effector arms of the adaptive immune system including specific IgM/IgG,
 38 humoral response and other immune response, as well as the innate immune system as
 39 shown by complement activation. Metabolites associated with immunity were also
 40 identified implicating the role of metabolites in the humoral response, complement
 41 activation and other immune response. Networks associated with the TCA cycle and
 42 amino acids metabolic pathways, such as phenylalanine metabolism, phenylalanine,
 43 tyrosine and tryptophan biosynthesis, and glycine, serine and threonine metabolism
 44 were tightly coupled with immunity. Critically, we constructed a multifactorial
 45 response network (MRN) to analyze the underlying interactions and compared the
 46 signatures affected by CoronaVac immunization and SARS-CoV-2 infection to
 47 further identify immune signatures and related metabolic pathways altered by
 48 CoronaVac immunization. These results suggest that protective immunity against
 49 SARS-CoV-2 can be achieved via multiple mechanisms and highlights the utility of a
 50 systems biology approach in defining molecular correlates of protection to
 51 vaccination.

52

53 **Keywords:** COVID-19; SARS-CoV-2; CoronaVac; Proteomics; Metabolomics;
 54 Immune response.

55 Introduction

56 The ongoing coronavirus disease 19 (COVID-19) pandemic, caused by severe acute
 57 respiratory syndrome coronavirus 2 (SARS-CoV-2), is an unprecedented global threat
 58 leading to high morbidity and mortality worldwide (Wang et al., 2020a). Since the
 59 outbreak began, researchers from around the world have been trying to develop
 60 vaccines for COVID-19, with more than 44 candidate vaccines in the clinical
 61 development stage and another 151 vaccines in preclinical evaluation as of February,
 62 2021(Hodgson et al., 2021). CoronaVac (Sinovac Life Sciences, Beijing, China), an
 63 inactivated vaccine against COVID-19 has shown good immunogenicity in mice, rats,
 64 and non-human primates (Wu et al., 2021; Zhang et al., 2021)). After preclinical
 65 evaluation, CoronaVac, approved by the WHO recently, has been widely used in
 66 China and other countries to immunize different populations, including children and
 67 adolescents aged 3-17 years old, adults aged 18-59, and adults aged 60 years and
 68 older (Mallapaty, 2021)

69 Although the efficacy of CoronaVac has been assessed in large clinical trials
 70 involving thousands of subjects, the underlying molecular processes and cellular
 71 mechanisms by which biological messages stimulate the immune response remains
 72 poorly understood (Wu et al., 2021; Zhang et al., 2021). Previous analysis of
 73 COVID-19 vaccines has mainly focused on evaluating immunogenicity and safety, as
 74 well as characterizing immune cell types and/or cytokines (Polack et al., 2020; Wu et
 75 al., 2021; Zhang et al., 2021). Protective immunity induced by vaccines not only
 76 involves the response of the innate and adaptive immune cells, but also induces
 77 profound changes in cellular proteomic and metabolic pathways, increasing the
 78 capacity of these immune cells to respond to secondary stimulation. Systems
 79 vaccinology, which uses high-throughput cellular and molecular omics technologies,
 80 allows the immune response to be comprehensively studied to increase our
 81 understanding of vaccine-induced immunity (Li et al., 2017; Nakaya et al., 2015;
 82 Tsang et al., 2014). Being able to quickly determine vaccine efficacy, and specific
 83 protein and metabolite changes would aid in controlling epidemics and pandemics

84 when speed is a critical factor.

85 Blood proteomics and metabolomics have provided valuable insights into the
86 early events of vaccine-induced immune response (Best et al., 2018; Camponovo et
87 al., 2020; Rieckmann et al., 2017). For example, proteomic signatures after
88 vaccination have been used to predict vaccine-induced T cell responses in multiple
89 studies, and different classes of vaccines have been shown to induce distinct protein
90 expression patterns (Camponovo et al., 2020). The coordinated action of the immune
91 system induced by vaccines resembles a social network. This enables complex
92 immunological tasks to be performed beyond the sum of the functions of individual
93 immune cells (Li et al., 2017; Rieckmann et al., 2017). Furthermore, increasing
94 evidence have linked trained immunity to epigenetic and metabolic regulation that
95 involve a number of central cellular metabolic pathways such as glycolysis, oxidative
96 phosphorylation, glutaminolysis, as well as fatty acids and cholesterol-synthesis
97 pathways (Arts et al., 2016; Domínguez-Andrés et al., 2019; Voss et al., 2021).
98 Metabolic rewiring is a crucial step for the induction of trained immunity after
99 immunization, but many questions remain including which metabolic pathways are
100 involved (e.g. the role of pentose phosphate pathway or reactive oxygen species
101 metabolism), what immune cells are affected and what specific effects do these
102 metabolic changes have in the affected immune cells (Bekkering et al., 2018). Taken
103 together, proteomics and metabolic studies contribute to the emerging field of systems
104 vaccinology and open up new ways to understand the molecular mechanisms of
105 vaccine-induced immunity.

106 Beside efficacy, safety evaluation is another important parameter for vaccine
107 evaluation. Recently, a growing body of clinical data suggests that proteomic and
108 metabolic dysregulation are associated with COVID-19 pathogenesis (Shen et al.,
109 2020). For example, acute phase proteins (APPs) including serum amyloid A-1
110 (SAA1), SAA2, SAA4 and C-reactive protein (CRP) were increased in severe
111 COVID-19 patients, indicating activation of inflammation and the complement
112 system (Shen et al., 2020). This leads to enhanced cytokine and chemokine
113 production, potentially contributing to ‘cytokine storm’, and increases recruitment of

macrophages from peripheral blood, which may result in acute lung injury (Chirco and Potempa, 2018). In contrast to infection, the inflammatory response induced by the inactivated vaccine, CoronaVac, should be kept at an appropriate level while still promoting immune cell activation. For this reason, proteomic and metabolomic analysis of vaccine immunized subjects are essential in evaluating the safety of CoronaVac.

To enhance our understanding of the mechanisms behind CoronaVac-induced protection to SARS-CoV-2, we combined multi-omics data, including plasma proteomics, metabolomics, cytokine analysis, and specific IgM/IgG, coupled with computational approaches to construct a global overview of the immune response induced by CoronaVac. The goal of this study is 1) to evaluate the plasma proteomic and metabolomic phenotypes of adaptive immunity to CoronaVac, 2) to delineate the molecular mechanisms that generate protective immunity, and 3) to evaluate the safety of CoronaVac. Understanding how proteins and metabolites affect vaccine immune response has important implications for increasing vaccine efficacy and offering new insights into the molecular mechanisms of protection from SARS-CoV-2 vaccines.

RESULTS:

Study Design for Integrated Immune Profiling to CoronaVac Vaccination in Humans

Between January and April 2021, fifty participants, aged 18 to 65, were enrolled in Sanya People's Hospital and immunized with CoronaVac. The detailed descriptions including the sampling date for each participant are shown in **Figure 1A**, and **Table S1**. Participants received two doses of CoronaVac and were vaccinated at 21-33 days (d) intervals. The subjects' blood samples were collected at baseline (non-injection time point, NJ) prior to vaccination and at about 21 d after the first injection (FJ) and about 14 d after the second injection (SJ) time point, respectively (**Figure 1A**). Throughout the course of this study, we measured SARS-CoV-2-S-specific antibody

143 titers, clinical parameters and cytokines. Plasma proteomics and metabolomics were
144 also analyzed to obtain systems vaccinology data. As a result, each subject was
145 profiled by multiple technologies in a time series. This rich collection of immune
146 profiles, including high-dimensional data from proteomics and metabolomics,
147 provided a unique opportunity to construct an integrated network of the immune
148 response to CoronaVac in humans. For this study, we firstly present each data type
149 separately. Second, the integrative analysis is presented in a framework of a
150 “multifactorial response network” (MRN). Then, we compared the proteomic and
151 metabolomics signatures affected by CoronaVac vaccination and SARS-CoV-2
152 infection. The safety of CoronaVac was also evaluated using clinical indicators and
153 cytokines combined with proteomics and metabolomics results. Finally, the underling
154 mechanisms and pathways related to CoronaVac-induced immune response were
155 interpreted through a comprehensive analysis.

156

157 **CoronaVac-Induced Antibody Responses**

158 To ensure the effectiveness of vaccination, we assessed the antibody response to
159 SARS-CoV-2 induced by CoronaVac. At baseline, none of the participants had any
160 detectable S-specific IgG and IgM antibodies. The seroconversion rates of IgG were
161 18 (36%) at FJ point versus 50 (100%) of 50 participants at SJ point, and the
162 seroconversion rates of IgM were 2 (4%) at FJ point versus 25 (50%) of 50
163 participants at SJ point. The dynamic changes of IgG and IgM to SARS-CoV-2 are
164 shown in **Figure 1B** and illustrates that the IgG antibody levels did not significantly
165 increase until after the second dose of the vaccine. Additionally, as shown in **Figure**
166 **1C**, the levels of IgM and IgG were 2.562 ± 4.806 s/co and 19.691 ± 26.86 s/co at SJ
167 point, significantly higher than that at FJ point (IgM 0.388 ± 1.202 s/co, IgG
168 1.667 ± 3.21 s/co) and the baseline (IgM 0.024 ± 0.017 s/co, IgG 0.039 ± 0.075 s/co).
169 Taken together, these results show that CoronaVac induced antibody responses in all
170 subjects involved in this study. This was consistent with the increased antibody levels
171 reported in clinical trials (Wu et al., 2021; Zhang et al., 2021).

172

173 **Plasma Proteomic Signatures after CoronaVac Vaccination**

174 Based on the LC-MS/MS data, we identified 5054 peptides in total with 4400 peptides
175 (87.1%) supported by ≥ 2 MS/MS counts. These peptides were then mapped and 387
176 proteins (73.7%) were identified with $FDR \leq 1\%$ (**Figure S1A** and **Table S2**).

177 Of the 387 proteins, 116 were identified as differentially expressed proteins
178 (DEPs) in vaccine immunized samples compared to baseline (NJ). The number of
179 DEPs and magnitude of fold change were increased in the SJ group, indicating that
180 the alterations in plasma proteins became more extensive after the second dose of
181 CoronaVac (**Figure S2A-D** and **Table S3**). As expected, gene ontology (GO) terms
182 for DEPs were highly enriched in processes involved in known immune-related
183 functions, such as complement activation, regulation of complement activation,
184 humoral immune response, and regulation of humoral immune response (**Figure 2A**).
185 Interestingly, besides complement and coagulation cascades, KEGG analysis also
186 identified COVID-19 and pertussis pathways as significantly associated with
187 CoronaVac immunization (**Figure 2B**). GO and KEGG analysis of DEPs from FJ vs
188 NJ and SJ vs NJ also showed similar enrichment (**Figure S2 E-H**). As a COVID-19
189 inactivated vaccine, CoronaVac induced DEPs naturally enriched to COVID-19
190 pathway, suggesting that the adaptive immunity induced by CoronaVac were similar
191 with immunity induced by SARS-CoV-2 infection. Similar to our findings, *Reche et*
192 *al.*, (Reche, 2020) also found that pertussis vaccines contain cross-reactive epitopes
193 with SARS-CoV-2, and thus there may a general mechanism for cross-protection
194 between SARS-CoV-2 and pertussis. Cluster analysis showed that the expression of
195 DEPs can be divided into 8 different trends (**Figure S3A**).

197 **Evidence of Humoral and Complement Response Activation After CoronaVac** 198 **Immunization**

199 An important goal of systems vaccinology is to evaluate the adaptive response and
200 innate immunity to vaccination. Here, proteomics data showed that adaptive immunity,
201 especially humoral and complement response were activated by vaccination. As
202 shown in **Figure 2C**, 47 DEPs belonged to three major pathways: activation of the

complement response, humoral immune response, and other immune-associated pathways. At the SJ time point, multiple immunoglobulin heavy chains, including IGHA2, IGHG2, IGHG4, and IGKC were highly upregulated (**Figure 2C** and **Figure 2D**). Consistent with our report, expression of *IGHG2* and *IGKC* were also enhanced in subjects immunized with meningococcal vaccine, and correlated with immunogenicity (O'Connor et al., 2017). IGHG2 encodes the constant region of the heavy chain of IgG2, which is the predominant IgG subclass directed against specific antigens (Calonga-Solís et al., 2019). Increased expression of IgG in the plasma of vaccinated subjects also supports this finding (**Figure 1B**).

Complements were reported to have a protective role in enhancing virus neutralization by antibodies (Kurtovic and Beeson, 2021). It is also a central regulator for adaptive immune responses due to its essential role in delivering co-stimulatory signals via engagement of complement receptors on B and T cells (West et al., 2020). Although several recent studies have implicated complement activity or impairment in severe COVID-19 patients, the potential involvement of complement factors in protective immunity has been largely ignored for SARS-CoV-2 (Shen et al., 2020; Shu et al., 2020; Tian et al., 2020). In this study, we found that several complements, including C1QB, C1QC, C1RL, C2, C4BPA, C6, C7, and C8G were significantly increased at FJ and/or SJ time point (**Figure 2D**). Consistently, complements including C1QB were also found to be upregulated in blood cells early after yellow fever (YF17D) vaccination (Gaucher et al., 2008). These molecules have been shown to have a potential role in inducing dendritic cell maturation (Hosszu et al., 2012). Taken together, this suggests a possible role for the complement system in establishing protective immunity in response to CoronaVac vaccination.

In addition, other immune associated proteins were also observed to be increased in vaccine immunized subjects. For instance, it has been reported that ICAM-1 expression on DCs plays a crucial role in mediating T cell migration and activation (Boyd et al., 1988; Comrie et al., 2015). In this study, the level of ICAM-1 was significantly increased in immunized samples, implying the activation of T cells after vaccination. Human monocyte differentiation antigen CD14 is a pattern recognition

receptor that enhances the innate immune response and was significantly increased after the first immunization (Wu et al., 2019). Additionally, SERPINA1, important for the development of neutrophils, was also significantly increased in CoronaVac immunized samples. Similarly, the levels of SERPINA1 were also increased in BCG immunized samples, which indicates the induction of trained immunity in humans by vaccination (Cirovic et al., 2020). Collectively, our results demonstrate the activation of adaptive immunity, especially the humoral and complement responses, after CoronaVac vaccination.

To further understand the functions and interactions of DEPs induced by CoronaVac vaccination, we categorized these proteins based on GO biological processes (GO-BP) using the Cytoscape plug-in ClueGo (**Figure 2E**). All of the modules clustered into two groups, reflecting their functional lineage relationship. Among the 28 resulting functional modules, humoral regulated proteins were enriched for ‘regulation of humoral immune response’, ‘B cell mediated immunity’, ‘humoral immune response’ and ‘immunoglobulin mediated immune response’, and created a complex network. Humoral response was also tightly connected with complement-related modules such as complement activation, regulation of complement activation, and complement activation-classical pathway. Furthermore, the network of lymphocyte-related immunity, containing immunoglobulin proteins, was also significantly connected with the humoral and complement response network. The specialized function of complement, comprised of 12 proteins, was highly enriched for “complement activation” and “regulation of complement activation”. Notably, the proteins belonging to these modules were also connected with each other (**Figure 2F**). Together these results demonstrate that DEPs involved in adaptive immunity formed a complex interactive network which allowed us to further analyze the underlying mechanism of immunity induced by CoronaVac.

Plasma Metabolomic Signatures Induced by CoronaVac

To ensure reliable results, the PCA score plot, which included the control group, model group and QC samples, is shown in **Figure S1B**. QC samples (purple)

clustered tightly together, reflecting the stability of the instrument and showed that the quality of all the LC-MS data generated in this study was satisfactory. In addition, during the entire experiment, 88.68%, 37.8%, and 3% of the metabolite relative standard deviation (RSD) in the QC samples were within 30%, 15%, and 5%, respectively (**Figure S1C**). These results demonstrate the reliability of the analytical methods used.

We identified 1190 metabolites (**Table S2**). Compared to the baseline (NJ), 882 differentially expressed metabolites (DEMs), containing amino acids, lipids and other important serum metabolites, were identified. A summary of the number of DEMs between the vaccination and pre-vaccination cohorts is shown in **Figure 3A**. Further details of the DEMs from FJ vs NJ and SJ vs NJ are shown in **Figure S4** and **Table S4**. Not surprisingly, orthogonal partial least squares discrimination analysis (OPLS-DA) showed a high degree of separation between groups, illustrating evident differences in their plasma metabolite profiles (**Figure S1B**). Consistent with our proteomic data, the DEMs were also divided into 8 different clusters (**Figure S3B**). Metabolite Set Enrichment Analysis of DEMs revealed CoronaVac immunization had a significant impact on amino acid metabolism, especially pathways involving valine, leucine and isoleucine biosynthesis (**Figure 3B**). Moreover, the TCA cycle and other amino acid metabolism, such as phenylalanine metabolism, phenylalanine, tyrosine and tryptophan biosynthesis, and glycine, serine and threonine metabolism were also affected by vaccination. In comparison, DEMs of samples from subjects immunized with Zostavax and a *Francisella tularensis* vaccine were enriched for metabolites associated with the TCA cycle and 2-oxocarboxylic acid metabolism (Goll et al., 2020; Li et al., 2017). Notably, these results revealed distinct metabolomic signatures in the immune response to CoronaVac which provided key insights into vaccine-induced antiviral responses.

Metabolites associated with the Humoral and Complement Immune Response are altered after CoronaVac Immunization

292 A growing body of evidence suggests that metabolic pathways such as the TCA cycle,
 293 amino acid metabolism, and lipid metabolism, play an essential role in adaptive and
 294 innate immunity. To elucidate the role of metabolites in vaccine immunity, functional
 295 metabolites associated with immunity were selected for further analysis (**Figure S5**).
 296 Consistent with our proteomic analysis, 128 significant differentially expressed
 297 metabolites including carbohydrates, amino acids, and several types of lipids were
 298 involved in the three enriched biological processes identified in the proteomic
 299 analysis (**Figure 3C**). Production of antibody after vaccination is mainly mediated by
 300 plasma cells and requires large quantities of amino acids and glycosylation sugars to
 301 properly build and fold antibodies (Lam and Bhattacharya, 2018). In this study, we
 302 found significant changes in TCA intermediary metabolites (pyruvate, citrate,
 303 succinate, malate, and lactate) in vaccine immunized samples, implying involvement
 304 of the TCA cycle in vaccination (**Figure 4A**). The balance between energy and amino
 305 acid metabolism is essential for antibody production and in this study, we also
 306 identified more than 20 amino acids that were significantly altered in vaccine
 307 immunized samples compared to baseline samples (NJ). We found metabolites
 308 involved in arginine and proline metabolism were significantly changed after
 309 vaccination (**Figure 4B**). Arginine has been reported to participate in antibody
 310 synthesis (Fan et al., 2015). Additionally, several amino acids involved in
 311 phenylalanine metabolism were also significantly altered in vaccinated samples
 312 (**Figure 4C**). Phenylalanine metabolism is associated with humoral autoimmune
 313 diseases, which suggests an underlying function in the humoral response (Blackmore
 314 et al., 2020). Amino acids and metabolites involved in tryptophan metabolism were
 315 also significantly altered after CoronaVac immunization (**Figure S6A-B**). In addition,
 316 several fatty acids were also significantly changed in vaccinated samples (**Figure**
 317 **S6C**). These fatty acids may be important for the initial expansion of the endoplasmic
 318 reticulum during plasma cell differentiation (Dufort et al., 2014). Collectively, our
 319 results show that vaccination changes energy metabolism, amino acid metabolism and
 320 fatty acid metabolism. The balances of these metabolic pathways may play an
 321 important role in antibody production following vaccination.

Glycine, serine and threonine metabolism have been reported to affect complement-mediated killing (Cheng et al., 2019). In this study, L-cysteine, betaine, choline, and L-tryptophan, which are enriched in the glycine, serine and threonine metabolism pathway, were significantly changed in vaccine immunized samples (**Figure 4D**). In addition to antibody production and complement response, innate immunity was also linked to metabolic regulation and involved a number of central cellular metabolic pathways such as the TCA cycle, oxidative phosphorylation, as well as fatty acids and cholesterol-synthesis. Our data indicated that the innate immune system was activated after vaccination and this was accompanied by a series of related metabolites changing. For example, several fatty acids that were associated with proteins from the pathway “other immune-associated pathways”, have also been reported to be associated with a pro-inflammatory macrophage phenotype (**Figure 3C**) (Oishi et al., 2017). Taken together, our data suggests that altered metabolites may be a crucial step for adaptive immunity, and further integrated analysis will increase understanding of the underlying mechanism for how CoronaVac induces protection.

Multifactorial Response Network (MRN) Reveals a Connection between Antibody Response, Proteins, and Metabolites Following CoronaVac Immunization

To integrate antibody, proteomics, and metabolomics data, we constructed a MRN for mechanistic analysis. The MRN had a dense network of 329 nodes and 1395 connections. This hierarchical structure allows an overview of the super-network and reveals the complex relationship of the adaptive immune response induced by CoronaVac (**Figure 5A**).

A humoral response-related network was obtained to further investigate the underlying mechanisms following vaccination. As described above, levels of IGHA2, IGHG2, IGHG4, and IGKC correlated with antibody titers and were significantly increased after vaccination (**Figure 2D**). These proteins that were enriched in the humoral immune response were also connected with other immune response pathways such as immunoglobulin mediated immune response, humoral immune response

mediated by circulating immune and complement activation (**Figure S5D**). They were also correlated with the levels of IgG and expression of many enriched metabolites involved in biosynthesis of unsaturated fatty acids, the TCA cycle and several other amino acids pathways (**Figure S5D**). This suggests a connection between the antibody response and these metabolic pathways (**Figure 5B** and **Figure 5C**). We hypothesize that aminoacyl-tRNA biosynthesis, biosynthesis of unsaturated fatty acids and amino acid metabolic pathways such as tryptophan metabolism, alanine, aspartate and glutamate metabolism, and arginine and proline metabolism, which were all significantly altered following CoronaVac immunization at FJ and SJ timepoint are involved in and affects the antibody response (**Figure 5D**). In addition, after the second immunization, the TCA cycle, phenylalanine metabolism and the phenylalanine, tyrosine and tryptophan biosynthesis pathways were further altered by vaccination and may also be associated with the antibody response (**Figure 5E**). Finally, the humoral immune response pathway was also connected with complement activation and complement activation-classical pathway (which also showed tight correlation with the metabolism pathways mentioned above). Taken together, these data suggest that high activity in these metabolic pathways discussed above was detrimental to the humoral immune response induced by CoronaVac and they combined a complex network in which many proteins and metabolites are involved.

371

372 **Comparison of the Proteomic and Metabolomic Signatures Induced by** 373 **CoronaVac Immunization and SARS-CoV-2 Infection**

374 To gain an insight into the mechanisms underlying the responses to vaccines against
375 SARS-CoV-2, we combined data from a published paper (Shen et al., 2020) to
376 compare differences in the proteomic and metabolomic signatures affected by
377 vaccination and SARS-CoV-2 infection. Notably, DEPs in vaccination and infection
378 were different (**Figure 6A**). Interestingly, GO terms of DEPs after vaccination were
379 highly enriched in processes involved in known immune-related functions such as
380 complement activation, regulation of complement activation, humoral immune
381 response, and regulation of humoral immune response (**Figure 2A**). In comparison,

DEPs from COVID-19 patients were mainly enriched in platelet degranulation, regulation of hemostasis, blood coagulation, humoral immune response, complement activation, and acute-phase response (**Figure 6B** and **Figure 6C**) (**Shen et al., 2020**). Surprisingly however, several pathways related to immunity including humoral immune response, complement activation, regulation of complement activation and regulation of humoral immune response, which were induced by CoronaVac vaccination, were also strongly enriched in severe COVID-19 patients (**Figure 6D**). Enriched pathways unique to CoronaVac vaccination were complement activation-classical pathway and humoral immune response mediated by circulating immunoglobulin (**Figure 6E**). It was reported that SARS-CoV-2 infection induced dysregulation of macrophages, platelet degranulation and complement system pathways (Shen et al., 2020). Thus, DEPs related to macrophage function, platelet degranulation, and immune response were selected for further expression analysis (**Figure 6F**). Compared to infection, many circulating immunoglobulins and complements were elevated in CoronaVac immunized samples. For example, IGHA2 and IGHG2 were significantly increased after vaccination while they were not significant changed after infection. Both vaccines and infections lead to the activation of the complement system, but the phenotypes and underlying functions may be different. As shown in **Figure 6F**, C1QB, C1QC, and C7 were significantly increased after vaccination, while C5 and C8A were increased after infection. In addition, SARS-CoV-2 infection induced elevated acute phase proteins, including SAA1, SAA2, SAA4, CRP, alpha-1-antichymotrypsin (SERPINA3), and serum amyloid p-component (SAP/APCS) (Shen et al., 2020). As expected, except for SERPINA3 most acute phase proteins showed no changes following CoronaVac immunization. The potential function of SERPINA3 in COVID-19 should be studied further as it may be involved in immune cell infiltration (Xia et al., 2021). Besides acute phase proteins, a low platelet count was also reported to be associated with severe COVID-19 and mortality (Lippi et al., 2020). CoronaVac immunized samples did not alter the expression of plasma proteins such as platelet-expressing chemokines proplatelet basic protein (PPBP), platelet factor 4 (PF4) and other 10 platelet

412 associated proteins. Interestingly, proteins such as APOH, CLEC3B, HSPA5, and
413 AHSB also showed opposite trends between COVID-19 patients and CoronaVac
414 immunized subjects (Shen et al., 2020). These results indicate that CoronaVac does
415 not suppress platelet function.

416 Metabolomics phenotypes induced by vaccination and infection were also
417 significantly different (**Figure 7A**). Interestingly, there were some common
418 differentially expressed metabolites identified between vaccination and infection,
419 however, the expression trends were almost the opposite. For example, the levels of
420 tryptophan, leucine, betaine, isoleucine, citrate, and valine were decreased in
421 COVID-19 patients but increased in vaccination samples. Conversely, guanosine,
422 kynurenine and uracil were increased in COVID-19 patients but decreased in
423 vaccination samples (**Figure 7B**). Similar to vaccination, the metabolomics data for
424 COVID-19 infection also revealed a significant impact on amino acid metabolism.
425 However, the types of amino acid metabolism pathways affected by vaccination and
426 infection were different: COVID-19 infection mainly affected pathways involved in
427 valine, leucine and isoleucine biosynthesis, aminoacyl-tRNA biosynthesis, and
428 arginine biosynthesis (**Figure 7C** and **Figure 7D**). Compared to infection, vaccination
429 with CoronaVac significantly altered other pathways including: vitamin B6
430 metabolism, biosynthesis of unsaturated fatty acids, phenylalanine metabolism,
431 tryptophan metabolism, arginine and proline metabolism, and glycine, serine and
432 threonine metabolism (**Figure 7E** and **Figure 7F**). These data suggest that high
433 activity in amino acid metabolism, such as phenylalanine metabolism, tryptophan
434 metabolism, arginine and proline metabolism, and glycine, serine and threonine
435 metabolism as well as fatty acids pathway might be detrimental to humoral immune
436 responses. Altogether, vaccination caused a variety of unique proteomic and
437 metabolomic changes compared to infection, and these differences may play an
438 essential role in the protective mechanism induced by CoronaVac.

439

440 **Safety Evaluation of CoronaVac**

441 Safety evaluation is also an important goal in systems vaccinology. Previous data

442 have shown that SARS-CoV-2 infection causes a variety of disorders including
 443 “cytokine storm”, excessive inflammation, and suppressed platelet degranulation.
 444 COVID-19 may activate the ability of T cells to stimulate pro-inflammatory cytokines.
 445 Clinical reports show that both mild and severe forms of disease result in cytokine
 446 secretion, particularly IL-6, IL-1 β , TNF, GM-CSF, and IL-1 α (Wang et al., 2020b). In
 447 this study, no significant differences in inflammatory cytokines were observed in
 448 immunized samples; this was consistent with previous studies which also reported a
 449 lack of upregulated cytokines for subjects immunized with CoronaVac (**Table S5** and
 450 **Figure S7**) (Wu et al., 2021; Zhang et al., 2021)

451 Clinical laboratory-related factors are also associated with disease severity in
 452 COVID-19 patients. It was observed that SARS-CoV-2 induced higher expression of
 453 lymphocyte (Lym), monocyte (Mon), and white blood cells (WBC). A low platelet
 454 count was also reported to be associated with severe COVID-19 disease and mortality
 455 (Lippi et al., 2020). In this study, we analyzed 22 clinical measurements, including
 456 count and proportion of blood cells [white blood cells (WBC), red blood cell (RBC),
 457 neutrophils (Neu), lymphocyte (Lym), eosinophils (Eos), monocytes (Mon), basophils
 458 (Bas)], hemoglobin-related clinical indicators and platelet-related clinical indicators to
 459 evaluation the safety of CoronaVac. Compared to baseline (NJ), no significant
 460 changes except for eosinophils were observed in plasma from the immunized group
 461 (**Table S6** and **Figure S8**). Furthermore, the proteomic data also demonstrated that
 462 most acute phase proteins were not significantly altered during CoronaVac
 463 immunization (**Figure 2B**). Altogether, our data suggests that CoronaVac does not
 464 cause serious adverse reactions in immunized subjects.

465

466 Discussion

467 This study is, to our knowledge, the first study to combine multi-omics data, including
 468 plasma proteomics and metabolomics with cytokines, clinical index, and specific
 469 IgM/IgG for system biology analysis of CoronaVac. Previously, systems biology have
 470 been applied to identify signatures of immune responses to vaccination and have
 471 provided insights into the mechanisms of immune responses induced by different

472 vaccines such as the live attenuated yellow fever vaccine (YF-17D) (Gaucher et al.,
473 2008; Querec et al., 2009), smallpox vaccine (Reif et al., 2009), malaria vaccine
474 (Kazmin et al., 2017) and influenza vaccines (Nakaya et al., 2015). These insights can
475 be used to guide novel strategies for vaccine evaluation and design.

476 It was observed that CoronaVac can induce quick antibody responses which may
477 be suitable for emergency use and is of vital importance during the COVID-19
478 pandemic (Wu et al., 2021; Zhang et al., 2021). However, the underlying molecular
479 mechanisms induced by CoronaVac is still a mystery. Here, we combined proteomics
480 and metabolomics to identify the signatures associated with the immune response to
481 CoronaVac as changes in genes, proteins and metabolites may reflect the immune
482 status. It may also reveal the underlying molecular mechanisms involved in
483 vaccine-induced immunity. Our results showed that IgG and other immunoglobulin
484 components such as IGHA2, IGHG2, IGHG4, IGKC, and IGKV2-24, were
485 significantly elevated in vaccine immunized samples. IGHA2, IGHG2 and IGHG4 are
486 encoded by the immunoglobulin heavy chain (IGH) constant genes (*IGHC*), while
487 IGKC and IGKV2-24 are encoded by the subgroup of immunoglobulin light chain
488 genes (Walther et al., 2015). These results demonstrate the activation of B-cell and
489 plasma cells after vaccination which play an essential role in antiviral immunity. In
490 addition, the high expression of IGHG2 and IGHG4 might demonstrate that IgG2 and
491 IgG4 are the main type of IgG induced by CoronaVac. Previous multifactorial models
492 have also revealed integrated networks on humoral immunity induced by vaccination
493 against various other diseases (Camponovo et al., 2020; Li et al., 2014; Li et al., 2017;
494 O'Connor et al., 2017). For instance, herpes zoster (HZ) induced changes in genes and
495 metabolites associated with adaptive immunity and showed that sterol metabolism
496 was tightly coupled with immunity (Li et al., 2017). In Li et al., (Li et al., 2014) gene
497 expression data was collected from five different vaccine cohorts and revealed distinct
498 transcriptional signatures for antibody responses to different types of vaccines. The
499 study suggested that gene expression predictors for antibody response are probably
500 not 'universal' but are dependent on the type of vaccine, which is consistent with the
501 proposal that different types of vaccines would induce similar signatures of

immunogenicity. Consistent with other reports, our findings also support the humoral response as a key factor for antiviral immunity and that the immunity induced by CoronaVac showed distinctive characteristics.

Metabolites associated with humoral immunity were also revealed to play a potential role in the underlying mechanism for CoronaVac-induced immunity in this study. In our data, the essential intermediary metabolites in the TCA cycle were changed in vaccine immunized samples. These TCA cycle intermediary metabolites play a crucial role in regulating the immune system with some activating the immune response and others suppressing it (Choi et al., 2021). In cells with infection or other stresses, TCA cycle intermediates may accumulate and regulate inflammatory gene expression (Tannahill et al., 2013; Williams and O'Neill, 2018). Surprisingly, we found that most of the TCA cycle intermediates including pyruvate, citrate, malate and lactate were significantly decreased after vaccination and were negatively associated with IgG. These results suggest that vaccination does not trigger a severe inflammatory response like infection does, and that balancing TCA cycle intermediates could impact the immune response. Furthermore, the balance between energy and amino acid metabolism is essential for antibody production. As the central link to energy metabolism, metabolites in the TCA cycle are also involved in different amino acid metabolic pathways. In this study, vaccination also caused changes in amino acids and amino acid metabolic pathways such as arginine and proline metabolism, phenylalanine metabolism and glycine, serine and threonine metabolism. Although most of the metabolites were reported to be associated with antibody production, whether these amino acid metabolites also have other immunological roles after vaccination requires further investigation (Blackmore et al., 2020; Cheng et al., 2019; Fan et al., 2015).

Complements can also be activated by antigen-specific antibodies and therefore, can contribute to the adaptive immune responses (Mellors et al., 2020). However, few studies have focused on vaccine-induced complement responses. There have been several reports on the role of complement in COVID-19 disease in humans, however all were focused on innate complement activation that occurs during acute

infection(Shen et al., 2020; Tian et al., 2020). These studies have generally concluded that excess complement activity can contribute to severe disease pathology. Importantly, the potential involvement of complement factors in protective immunity has been largely ignored for SARS-CoV-2 but has been defined for other viruses, bacteria, and protozoa. Here, our results highlight that several kinds of complements were significantly increased after vaccination, implying that it might play a protective role and are consistent with Kurtovic's viewpoint (Kurtovic and Beeson, 2021). In other diseases, subjects immunized with the yellow fever vaccine, YF-17D, also showed activation of the complement system. C3a, a product of the classical complement enzymatic pathway was increased at day 7 after immunization (Querec et al., 2009). In addition, immunity to many viral and nonviral pathogens relies on antibodies and antibody-mediated neutralization. This has been demonstrated *in vitro* for the human pathogens; West Nile virus (Mehlhof et al., 2009), Nipah virus (Johnson et al., 2011), and others (Mellors J et al., 2020) using a combination of human and non-human antibodies and complements. It has also been suggested that COVID-19 patients with mild disease generally report normal serum concentrations of complement proteins, which suggests that these immune mediators may be able to contribute to immunity and reduce disease severity (Du et al., 2021). In line with this, an examination of >6000 COVID-19 patients found that individuals with a dysregulated complement system were more prone to developing severe disease than those with a healthy complement system (Ramlall et al., 2020). Furthermore, distinct components of the complement pathway were found to be essential for activating the innate immune response, including IFN-stimulated responsive element and nuclear factor- κ B reporters, against viral infection (Wang et al., 2012). Therefore, for most individuals, complement activation might contribute to reduced disease severity, whereas for a smaller percentage of individuals, the complement system might be dysregulated and associated with increased susceptibility to severe disease. The implications for antibody-complement interactions in virus neutralization and immunity should be further investigated and may have important implications for antibody-based vaccination strategies against SARS-CoV-2.

562 According to a phase 1/2 clinical trial, no vaccine-related serious adverse events
563 were reported (Wu et al., 2021; Zhang et al., 2021). Similarly, no “cytokine storm”
564 and changes in clinical index, except for slightly elevated eosinophils were observed
565 after vaccination in this study. In addition, systems vaccinology has also been applied
566 for safety evaluation. Mizukami et al. (Mizukami et al., 2014) applied a systems
567 vaccinology approach in a rat model to predict safety and batch-to-batch consistency
568 of influenza vaccines. In this study, most acute phase proteins, such as SAA1, SAA2,
569 SAA4, CRP, SERPINA3, and SAP/APCS, which were increased in severe COVID-19
570 patients were not changed in our CoronaVac immunized samples. The plasma
571 proteomic and metabolic signatures of vaccine immunized samples were also different
572 from that of COVID-19 patients, further supporting the idea that this inactivated
573 vaccine was safe.

574 It should be noted that although secreted proteins and metabolites can directly
575 reflect the immune status, they contain less information than the transcriptome and
576 will be analyzed in future studies. Additionally, this was a single-center prospective
577 study with a relatively small sample size and missing values, which are common in
578 LC-MS data and may affect data interpretation in studies with smaller sample sizes.
579 Therefore, future large-sized cohort studies are warranted to confirm the findings in
580 this study.

581 In conclusion, our systems vaccinology study showed that CoronaVac
582 immunization was safe and induced humoral immune responses against SARS-CoV-2.
583 These results support the approval for emergency use of CoronaVac in China. The
584 differentially expressed proteins and metabolites identified formed a complex network
585 that resulted in vaccine-induced antiviral immunity. MRN analysis and comparison
586 between CoronaVac vaccination and SARS-CoV-2 infection indicated that humoral
587 and complement responses as well as several metabolic pathways, including the TCA
588 cycle, phenylalanine metabolism, tryptophan metabolism, arginine, proline
589 metabolism and fatty acids pathways, might be essential for protective immunity
590 induced by CoronaVac.

591

592 **Material and methods**

593 **Experimental design and participant recruitment**

594 A total of 50 subjects immunized with the COVID-19 vaccine, CoronaVac, were
595 recruited. Written informed consent was obtained from each subject and protocols
596 were approved by Institutional Review Boards of Sayan People's Hospital.

598 **COVID-19-specific IgM/IgG ELISA**

599 The S-specific IgG and IgM were detected using a chemiluminescence quantitative kit
600 (Auto Biotechnology, Zhengzhou, China). Plates were coated with either
601 SARS-CoV-2 recombinant antigens or mouse anti-human IgM monoclonal antibody.
602 Ten μL of sample, 20 μL of microparticle solution and 100 μL of sample diluent were
603 mixed and incubated for 37 min at 37°C . The plates were then washed and enzyme
604 conjugates were added, and incubated for 17 min at 37°C . Plates were washed and
605 chemiluminescence developed using 50 μL Chemiluminescent Substrate A and 50 μL
606 of Chemiluminescent Substrate B. The antibody titer was measured using the
607 AutoLumo A2000 Plus. Results with $S/CO \geq 1.00$ were considered positive while
608 $S/CO < 1.00$ were considered negative.

610 **Evaluation of clinical characteristics and markers**

611 Complete information, including count and proportion of blood cells [white blood
612 cells (WBC), red blood cell (RBC), neutrophils (Neu), lymphocyte (Lym), eosinophils
613 (Eos), monocytes (Mon), basophils (Bas)], hemoglobin-related clinical indicators
614 including hemoglobin(HGB), hematocrit (HCT), mean corpuscular volume (MCV),
615 mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration
616 (MCHC), red blood cell distribution width-coefficient of variation (RDW-CV), red
617 blood cell distribution width-standard deviation (RDW-SD), and platelet-related
618 clinical indicators including platelet (PLT), platelet volume distribution width (PDW),
619 plateletcrit (PCT) were analyzed using the Sysmex XE-2100 (Sysmex Corporation).

620

621 **Multiplex cytokine assays**

622 Concentrations of granulocyte-macrophage colony stimulating factor (GM-CSF),
623 interferon (IFN)- γ , Interleukin (IL)-1 β , IL-12, IL-13, IL-18, IL-2, IL-4, IL-5, IL-6 and
624 tumor necrosis factor (TNF)- α in plasma were determined using a bead-based, 11-plex
625 Th1/Th2 human ProcartaPlex immunoassay (Thermo Fisher Scientific) according to
626 the manufacturer's instructions. Fluorescence was measured with a Luminex 200
627 system (Luminex Corporation) and analyzed with ProcartaPlex Analyst 1.0 software
628 (Thermo Fisher Scientific). Only cytokines above the limit of detection were included
629 for further analysis.

631 **Plasma proteomics**

632 Ten of the fifty subjects were randomly selected for plasma proteomic analysis. To
633 remove highly abundant interfering proteins in human plasma, a multiple-affinity
634 removal system liquid chromatography (LC) column (High Select™ Top14 Abundant
635 Protein Depletion Mini Spin Columns; Thermo Fisher Technologies, Santa Clara, CA,
636 USA) was used. Briefly, plasma samples loaded onto a multiple-affinity removal
637 system LC column were eluted into fractions which contained low-abundance
638 proteins while highly abundant proteins were removed. The eluted product was used
639 for MS analysis. The concentration of plasma proteins was measured and 50 μ g
640 protein samples were prepared for mass spectrometry analysis.

641 Plasma from each sample was lysed in 100 μ L lysis buffer (8 M urea in 100 mM
642 triethylammonium bicarbonate, TEAB) at 25°C for 30 min. The lysates were reduced
643 using 5 mM Tris (2-carboxyethyl) phosphine (Pierce, Rockford, IL, USA) and
644 incubated at 37°C for 30 min with shaking (300 rpm). For alkylation, 15 mM
645 Iodoacetamide (Sigma-Aldrich, St. Louis, MO, USA) was added to each sample and
646 incubated at 25°C, with agitation at 300 rpm for 1 h in the dark. Proteins were trypsin
647 digested overnight at 37°C. Mass spectrometry-grade trypsin gold (Promega, Madison,
648 WI, USA) was used with an enzyme-to-protein ratio of 1:50. The dried peptides were
649 dissolved in 20 μ L loading buffer (1% formic acid, FA; 1% acetonitrile, ACN). Ten μ L
650 of sample was used for LC-MS/MS analysis on an Orbitrap Fusion Lumos in data

dependent acquisition (DDA) mode coupled with Ultimate 3000 (Thermo Fisher Scientific, Waltham, MA, USA). The samples were loaded and separated by a C18 trap column (3mm 0.10×20mm), packed with C18 reverse phase particle (1.9mm 0.15×120mm, Phenomenex, Torrance, California, USA). The peptides were eluted using a 75 min nonlinear gradient: 7% B for 11 min, 15–25% B for 37 min, 25–40% B for 20 min, 40–100% B for 1 min, 100% B for 6min (Buffer A, 0.1% FA in ddH₂O; Buffer B, 0.1% FA and 80% ACN in ddH₂O; flow rate, ~600 nL/min). All reagents used were MS grade.

The parameters for MS detection were as follows: full MS survey scans were performed in the ultra-high-field Orbitrap analyzer at a resolution of 120,000 and trap size of 500,000 ions over a mass range from 300 to 1400 m/z. MS/MS scan were detected in IonTrap and the 20 most intense peptide ions with charge states 2 to 7 were subjected to fragmentation via higher energy collision-induced dissociation (5×10^3 AGC target, 35 ms maximum ion time). The resultant mass spectrometry data were analyzed using Maxquant (Version 1.6.17) and the protein search database used was the *Homo sapiens* FASTA database downloaded from UniprotKB (UP000005640.fasta). The following search parameters were used for Maxquant: precursor ion mass tolerance was set at 20 ppm; full cleavage by trypsin was selected; a maximum of two missed cleavages was allowed; static modifications were set to carbamidomethylation (+57.021464) of cysteine, and variable modifications were set to oxidation (+15.994915) of methionine and acetylation (+42.010565) of peptides' N-termini. The remaining parameters followed the default Maxquant setup. For protein identification, the following criteria was used: (1) peptide length ≥ 6 amino acids; (2) FDR $\leq 1\%$ at the PSM, peptide and protein levels. Peptides were quantified using the peak area derived from their MS1 intensity. The intensity of unique and razor peptides was used to calculate the protein intensity.

677

678 **Plasma metabolomics**

Participant plasma, which were immediately stored at -80°C upon collection, was thawed on ice. To ensure data quality for metabolic profiling, pooled quality control

681 samples were prepared by mixing equal amounts of plasma (0.75 mL) from 150
 682 samples. The pretreatment of the QC samples was performed in parallel and was the
 683 same as the study samples. The QC samples were evenly inserted between each set of
 684 runs to monitor the stability of the large-scale analysis. Plasma samples were
 685 extracted by adding 400 μ L of MeOH/ACN (1:1, v/v) solvent mixture to 100 μ L of
 686 plasma (2:2:1 ratio, no H₂O added). The mixtures were shaken vigorously for 5 min
 687 and incubated for 1 h at -20°C. Samples were then centrifuged for 10 minutes at
 688 13,500 x g at 4°C and the supernatant was transferred to a new centrifuge tube. To
 689 ensure that the metabolites detected were reliable, three platforms were used for
 690 shotgun metabolomics. Each supernatant was divided into three fractions: two for
 691 reverse-phase/ultra-performance liquid chromatography (RP/UPLC)-MS/MS methods
 692 with positive ion-mode electrospray ionization (ESI) and negative-ion mode ESI, and
 693 one for hydrophilic interaction liquid chromatography (HILIC)/UPLC-MS/MS with
 694 positive-ion mode ESI.

695 All UPLC-MS/MS methods used the ACQUITY 2D UPLC system (Waters,
 696 Milford, MA, USA) and Q-Exactive Quadrupole-Orbitrap (Thermo Fisher
 697 Scientific™, San Jose, USA) and TripleTOF 5600+ (AB SCIEX, MA, USA) with ESI
 698 source and mass analyzer. In the UPLC-MS/MS method, the QE was operated under
 699 positive electron spray ionization (ESI) coupled with a C18 column (UPLC BEH C18,
 700 2.1 $\times$ 100 mm, 1.7 μ m; Waters). The mobile solutions used in the gradient elution
 701 were water and methanol containing 0.1% FA. When the QE was operated under
 702 negative ESI mode, the UPLC method used a C18 column eluted with mobile
 703 solutions containing methanol and water in 6.5 mM ammonium bicarbonate at pH 8.
 704 The UPLC column used in the hydrophilic interaction method was a HILIC column
 705 (UPLC BEH Amide, 2.1 $\times$ 150 mm, 1.7 μ m; Waters), and the mobile solutions
 706 consisted of water and acetonitrile with 9 mM ammonium formate at pH 8.0; the
 707 TripleTOF 5600+ was operated under positive ESI mode. The mass spectrometry
 708 analysis alternated between MS and data-dependent MS2 scans using dynamic
 709 exclusion. The scan range was 70-1,000 m/z. After raw data pre-processing, peak
 710 finding/alignment, and peak annotation using MSDIAL software, metabolite

711 identifications were supported by matching the retention time, accurate mass, and
712 MS/MS fragmentation data to MSDIAL software database and online MS/MS
713 libraries (Human Metabolome Database (HMDB, <https://hmdb.ca>). Open database
714 sources including KEGG and MetaboAnalyst, Human Metabolome Database, were
715 used to identify metabolic pathways.

716

717 **Statistical analysis**

718 All missing values were substituted with 1/5 the minimal value. Missing values were
719 imputed with the minimal value for each feature. The influence of age and sex to the
720 proteomic profiling was assessed using partial least squares regression. For each
721 comparison, the log2 fold-change (log2 FC) was calculated by averaging the paired
722 fold change for each participant. A two-sided paired Welch's t test was also performed.
723 Statistical significance and differentially expressed proteins were assigned as p value
724 <0.05 and absolute log2 FC >0.25 . The correlation between IgG and metabolites was
725 analyzed using Pearson's correlation ($p < 0.05$).

726 Orthogonal partial least squares discrimination analysis (OPLS-DA) and partial
727 least squares-discriminate analysis (PLS-DA) was conducted using MetaboAnalyst
728 5.0 (<http://www.metaboanalyst.ca/MetaboAnalyst/>). Volcano plots were calculated
729 using a combination of fold-change and paired Welch's t test. The intensity data of
730 these regions were used in box-plot analysis and hierarchical cluster analysis. Heat
731 maps of differential metabolites and relationships were displayed using the Multi
732 Experiment Viewer software (MeV, version 4.7.4). Pathway analysis and visualization
733 were performed using the Metaboanalyst5.0 web portal
734 (<http://www.metaboanalyst.ca/>).

735 Connected networks of the differentially expressed proteins were built and
736 analyzed in BINGO. Metscape was used to build the network of metabolites, analyze
737 the correlation of these different metabolites and visualize the-networks. Heat map,
738 column chart, radar map, cluster were made using R packets.

739 **Funding:** This work was supported by grants from State Key Laboratory of Infectious
740 Disease Prevention and Control (2020SKLID303), Public service development and
741 reform pilot project of Beijing Medical Research Institute (BMR2019-11), National
742 natural science foundation of China (81970900) and Beijing Social Science
743 Foundation Project (19GLB033).

744 **Ethical approval:** This study was approved by the Ethics Committee of the Sanya
745 People's Hospital (SYPH-2021-26).

746 **Data sharing:** No additional data available.

747 **Transparency declaration:** The lead author and guarantor affirms that the
748 manuscript is an honest, accurate, and transparent account of the study being reported;
749 that no important aspects of the study have been omitted; and that any discrepancies
750 from the study as planned and registered have been explained.

751 **Acknowledgments**

752 We thank all the participants. We gratefully acknowledge the participation of
753 Fan Xing Biological Technology Co., Ltd. (Tianjin) for the support of bioinformatics
754 analysis with their Analysis Platform, and thanks Miss. Yan Li for her contribution.

755

756 **References:**

- 757 Arts, R.J., Novakovic, B., Ter Horst, R., Carvalho, A., Bekkering, S., Lachmandas, E.,
758 Rodrigues, F., Silvestre, R., Cheng, S.C., Wang, S.Y., *et al.* (2016). Glutaminolysis and
759 Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained
760 Immunity. *Cell metabolism* 24, 807-819.
- 761 Bekkering, S., Arts, R.J.W., Novakovic, B., Kourtzelis, I., van der Heijden, C., Li, Y., Popa,
762 C.D., Ter Horst, R., van Tuijl, J., Netea-Maier, R.T., *et al.* (2018). Metabolic Induction of
763 Trained Immunity through the Mevalonate Pathway. *Cell* 172, 135-146.e139.
- 764 Best, S.A., De Souza, D.P., Kersbergen, A., Policheni, A.N., Dayalan, S., Tull, D., Rath, V.,
765 Gray, D.H., Ritchie, M.E., McConville, M.J., and Sutherland, K.D. (2018). Synergy between the
766 KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered
767 Immune Microenvironment. *Cell metabolism* 27, 935-943.e934.
- 768 Blackmore, D., Li, L., Wang, N., Maksymowych, W., Yacyshyn, E., and Siddiqi, Z.A. (2020).
769 Metabolomic profile overlap in prototypical autoimmune humoral disease: a comparison of
770 myasthenia gravis and rheumatoid arthritis. *Metabolomics : Official journal of the Metabolomic*
771 *Society* 16, 10.
- 772 Boyd, A.W., Wawryk, S.O., Burns, G.F., and Fecondo, J.V. (1988). Intercellular adhesion
773 molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms.
774 *Proceedings of the National Academy of Sciences of the United States of America* 85,
775 3095-3099.
- 776 Calonga-Solís, V., Malheiros, D., Beltrame, M.H., Vargas, L.B., Dourado, R.M., Issler, H.C.,
777 Wassem, R., Petzl-Erler, M.L., and Augusto, D.G. (2019). Unveiling the Diversity of

778 Immunoglobulin Heavy Constant Gamma (IGHG) Gene Segments in Brazilian Populations
779 Reveals 28 Novel Alleles and Evidence of Gene Conversion and Natural Selection. *Frontiers*
780 *in immunology* *10*, 1161.

781 Camponovo, F., Campo, J.J., Le, T.Q., Oberai, A., Hung, C., Pablo, J.V., Teng, A.A., Liang, X.,
782 Sim, B.K.L., Jonga, S., *et al.* (2020). Proteome-wide analysis of a malaria vaccine study
783 reveals personalized humoral immune profiles in Tanzanian adults. *eLife* *9*.

784 Cheng, Z.X., Guo, C., Chen, Z.G., Yang, T.C., Zhang, J.Y., Wang, J., Zhu, J.X., Li, D., Zhang,
785 T.T., Li, H., *et al.* (2019). Glycine, serine and threonine metabolism confounds efficacy of
786 complement-mediated killing. *Nature communications* *10*, 3325.

787 Chirco, K.R., and Potempa, L.A. (2018). C-Reactive Protein As a Mediator of Complement
788 Activation and Inflammatory Signaling in Age-Related Macular Degeneration. *Frontiers in*
789 *immunology* *9*, 539.

790 Choi, I., Son, H., and Baek, J.H. (2021). Tricarboxylic Acid (TCA) Cycle Intermediates:
791 Regulators of Immune Responses. *Life (Basel, Switzerland)* *11*.

792 Cirovic, B., de Bree, L.C.J., Groh, L., Blok, B.A., Chan, J., van der Velden, W., Bremmers,
793 M.E.J., van Crevel, R., Händler, K., Picelli, S., *et al.* (2020). BCG Vaccination in Humans
794 Elicits Trained Immunity via the Hematopoietic Progenitor Compartment. *Cell host & microbe*
795 *28*, 322-334.e325.

796 Comrie, W.A., Li, S., Boyle, S., and Burkhardt, J.K. (2015). The dendritic cell cytoskeleton
797 promotes T cell adhesion and activation by constraining ICAM-1 mobility. *The Journal of cell*
798 *biology* *208*, 457-473.

799 Domínguez-Andrés, J., Joosten, L.A., and Netea, M.G. (2019). Induction of innate immune

memory: the role of cellular metabolism. *Current opinion in immunology* *56*, 10-16.

Du, H., Dong, X., Zhang, J.J., Cao, Y.Y., Akdis, M., Huang, P.Q., Chen, H.W., Li, Y., Liu, G.H., Akdis, C.A., *et al.* (2021). Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status. *Allergy* *76*, 510-532.

Dufort, F.J., Gumina, M.R., Ta, N.L., Tao, Y., Heyse, S.A., Scott, D.A., Richardson, A.D., Seyfried, T.N., and Chiles, T.C. (2014). Glucose-dependent de novo lipogenesis in B lymphocytes: a requirement for atp-citrate lyase in lipopolysaccharide-induced differentiation. *The Journal of biological chemistry* *289*, 7011-7024.

Fan, Y., Jimenez Del Val, I., Müller, C., Wagtberg Sen, J., Rasmussen, S.K., Kontoravdi, C., Weilguny, D., and Andersen, M.R. (2015). Amino acid and glucose metabolism in fed-batch CHO cell culture affects antibody production and glycosylation. *Biotechnology and bioengineering* *112*, 521-535.

Gaucher, D., Therrien, R., Kettaf, N., Angermann, B.R., Boucher, G., Filali-Mouhim, A., Moser, J.M., Mehta, R.S., Drake, D.R., 3rd, Castro, E., *et al.* (2008). Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. *The Journal of experimental medicine* *205*, 3119-3131.

Goll, J.B., Li, S., Edwards, J.L., Bosinger, S.E., Jensen, T.L., Wang, Y., Hooper, W.F., Gelber, C.E., Sanders, K.L., Anderson, E.J., *et al.* (2020). Transcriptomic and Metabolic Responses to a Live-Attenuated *Francisella tularensis* Vaccine. *Vaccines* *8*.

Hodgson, S.H., Mansatta, K., Mallett, G., Harris, V., Emary, K.R.W., and Pollard, A.J. (2021). What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. *The Lancet. Infectious diseases* *21*,

822 e26-e35.

823 Hosszu, K.K., Valentino, A., Vinayagasundaram, U., Vinayagasundaram, R., Joyce, M.G., Ji,

824 Y., Peerschke, E.I., and Ghebrehiwet, B. (2012). DC-SIGN, C1q, and gC1qR form a

825 trimolecular receptor complex on the surface of monocyte-derived immature dendritic cells.

826 *Blood* 120, 1228-1236.

827 Johnson, J.B., Aguilar, H.C., Lee, B., and Parks, G.D. (2011). Interactions of human

828 complement with virus particles containing the Nipah virus glycoproteins. *Journal of virology*

829 85, 5940-5948.

830 Kazmin, D., Nakaya, H.I., Lee, E.K., Johnson, M.J., van der Most, R., van den Berg, R.A.,

831 Ballou, W.R., Jongert, E., Wille-Reece, U., Ockenhouse, C., *et al.* (2017). Systems analysis of

832 protective immune responses to RTS,S malaria vaccination in humans. *Proceedings of the*

833 *National Academy of Sciences of the United States of America* 114, 2425-2430.

834 Kurtovic, L., and Beeson, J.G. (2021). Complement Factors in COVID-19 Therapeutics and

835 Vaccines. *Trends in immunology* 42, 94-103.

836 Lam, W.Y., and Bhattacharya, D. (2018). Metabolic Links between Plasma Cell Survival,

837 Secretion, and Stress. *Trends in immunology* 39, 19-27.

838 Li, S., Roupael, N., Duraisingham, S., Romero-Steiner, S., Presnell, S., Davis, C., Schmidt,

839 D.S., Johnson, S.E., Milton, A., Rajam, G., *et al.* (2014). Molecular signatures of antibody

840 responses derived from a systems biology study of five human vaccines. *Nature immunology*

841 15, 195-204.

842 Li, S., Sullivan, N.L., Roupael, N., Yu, T., Banton, S., Maddur, M.S., McCausland, M., Chiu,

843 C., Canniff, J., Dubey, S., *et al.* (2017). Metabolic Phenotypes of Response to Vaccination in

844 Humans. *Cell* **169**, 862-877.e817.

845 Lippi, G., Plebani, M., and Henry, B.M. (2020). Thrombocytopenia is associated with severe
846 coronavirus disease 2019 (COVID-19) infections: A meta-analysis. *Clinica chimica acta;*
847 *international journal of clinical chemistry* **506**, 145-148.

848 Mallapaty, S. (2021). WHO approval of Chinese CoronaVac COVID vaccine will be crucial to
849 curbing pandemic. *Nature* **594**, 161-162.

850 Mehlhop, E., Nelson, S., Jost, C.A., Gorlatov, S., Johnson, S., Fremont, D.H., Diamond, M.S.,
851 and Pierson, T.C. (2009). Complement protein C1q reduces the stoichiometric threshold for
852 antibody-mediated neutralization of West Nile virus. *Cell host & microbe* **6**, 381-391.

853 Mellors, J., Tipton, T., Longet, S., and Carroll, M. (2020). Viral Evasion of the Complement
854 System and Its Importance for Vaccines and Therapeutics. *Frontiers in immunology* **11**, 1450.

855 Mizukami, T., Momose, H., Kuramitsu, M., Takizawa, K., Araki, K., Furuhashi, K., Ishii, K.J.,
856 Hamaguchi, I., and Yamaguchi, K. (2014). System vaccinology for the evaluation of influenza
857 vaccine safety by multiplex gene detection of novel biomarkers in a preclinical study and batch
858 release test. *PloS one* **9**, e101835.

859 Nakaya, H.I., Hagan, T., Duraisingham, S.S., Lee, E.K., Kwissa, M., Roupael, N., Frasca, D.,
860 Gersten, M., Mehta, A.K., Gaujoux, R., *et al.* (2015). Systems Analysis of Immunity to
861 Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared
862 Molecular Signatures. *Immunity* **43**, 1186-1198.

863 O'Connor, D., Clutterbuck, E.A., Thompson, A.J., Snape, M.D., Ramasamy, M.N., Kelly, D.F.,
864 and Pollard, A.J. (2017). High-dimensional assessment of B-cell responses to quadrivalent
865 meningococcal conjugate and plain polysaccharide vaccine. *Genome medicine* **9**, 11.

866 Oishi, Y., Spann, N.J., Link, V.M., Muse, E.D., Strid, T., Edillor, C., Kolar, M.J., Matsuzaka, T.,
867 Hayakawa, S., Tao, J., *et al.* (2017). SREBP1 Contributes to Resolution of Pro-inflammatory
868 TLR4 Signaling by Reprogramming Fatty Acid Metabolism. *Cell metabolism* *25*, 412-427.
869 Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L.,
870 Pérez Marc, G., Moreira, E.D., Zerbini, C., *et al.* (2020). Safety and Efficacy of the BNT162b2
871 mRNA Covid-19 Vaccine. *The New England journal of medicine* *383*, 2603-2615.
872 Querec, T.D., Akondy, R.S., Lee, E.K., Cao, W., Nakaya, H.I., Teuwen, D., Pirani, A., Gernert,
873 K., Deng, J., Marzolf, B., *et al.* (2009). Systems biology approach predicts immunogenicity of
874 the yellow fever vaccine in humans. *Nature immunology* *10*, 116-125.
875 Ramlall, V., Thangaraj, P.M., Meydan, C., Foox, J., Butler, D., Kim, J., May, B., De Freitas,
876 J.K., Glicksberg, B.S., Mason, C.E., *et al.* (2020). Immune complement and coagulation
877 dysfunction in adverse outcomes of SARS-CoV-2 infection. *Nature medicine* *26*, 1609-1615.
878 Reche, P.A. (2020). Potential Cross-Reactive Immunity to SARS-CoV-2 From Common
879 Human Pathogens and Vaccines. *Frontiers in immunology* *11*, 586984.
880 Reif, D.M., Motsinger-Reif, A.A., McKinney, B.A., Rock, M.T., Crowe, J.E., Jr., and Moore, J.H.
881 (2009). Integrated analysis of genetic and proteomic data identifies biomarkers associated
882 with adverse events following smallpox vaccination. *Genes and immunity* *10*, 112-119.
883 Rieckmann, J.C., Geiger, R., Hornburg, D., Wolf, T., Kveler, K., Jarrossay, D., Sallusto, F.,
884 Shen-Orr, S.S., Lanzavecchia, A., Mann, M., and Meissner, F. (2017). Social network
885 architecture of human immune cells unveiled by quantitative proteomics. *Nature immunology*
886 *18*, 583-593.
887 Shen, B., Yi, X., Sun, Y., Bi, X., Du, J., Zhang, C., Quan, S., Zhang, F., Sun, R., Qian, L., *et al.*

888 (2020). Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. *Cell* **182**,
889 59-72.e15.

890 Shu, T., Ning, W., Wu, D., Xu, J., Han, Q., Huang, M., Zou, X., Yang, Q., Yuan, Y., Bie, Y., *et*
891 *al.* (2020). Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19. *Immunity*
892 **53**, 1108-1122.e1105.

893 Tannahill, G.M., Curtis, A.M., Adamik, J., Palsson-McDermott, E.M., McGettrick, A.F., Goel, G.,
894 Frezza, C., Bernard, N.J., Kelly, B., Foley, N.H., *et al.* (2013). Succinate is an inflammatory
895 signal that induces IL-1 β through HIF-1 α . *Nature* **496**, 238-242.

896 Tian, W., Zhang, N., Jin, R., Feng, Y., Wang, S., Gao, S., Gao, R., Wu, G., Tian, D., Tan, W.,
897 *et al.* (2020). Immune suppression in the early stage of COVID-19 disease. *Nature*
898 *communications* **11**, 5859.

899 Tsang, J.S., Schwartzberg, P.L., Kotliarov, Y., Biancotto, A., Xie, Z., Germain, R.N., Wang, E.,
900 Olnes, M.J., Narayanan, M., Golding, H., *et al.* (2014). Global analyses of human immune
901 variation reveal baseline predictors of postvaccination responses. *Cell* **157**, 499-513.

902 Voss, K., Hong, H.S., Bader, J.E., Sugiura, A., Lyssiotis, C.A., and Rathmell, J.C. (2021). A
903 guide to interrogating immunometabolism. *Nature reviews. Immunology*.

904 Walther, S., Rusitzka, T.V., Diesterbeck, U.S., and Czerny, C.P. (2015). Equine
905 immunoglobulins and organization of immunoglobulin genes. *Developmental and comparative*
906 *immunology* **53**, 303-319.

907 Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y.,
908 *et al.* (2020a). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel
909 Coronavirus-Infected Pneumonia in Wuhan, China. *Jama* **323**, 1061-1069.

910 Wang, J., Jiang, M., Chen, X., and Montaner, L.J. (2020b). Cytokine storm and leukocyte
911 changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in
912 China and emerging pathogenesis and therapy concepts. *Journal of leukocyte biology* *108*,
913 17-41.

914 Wang, Y., Tong, X., Zhang, J., and Ye, X. (2012). The complement C1qA enhances retinoic
915 acid-inducible gene-I-mediated immune signalling. *Immunology* *136*, 78-85.

916 West, E.E., Kunz, N., and Kemper, C. (2020). Complement and human T cell metabolism:
917 Location, location, location. *Immunological reviews* *295*, 68-81.

918 Williams, N.C., and O'Neill, L.A.J. (2018). A Role for the Krebs Cycle Intermediate Citrate in
919 Metabolic Reprogramming in Innate Immunity and Inflammation. *Frontiers in immunology* *9*,
920 141.

921 Wu, Z., Hu, Y., Xu, M., Chen, Z., Yang, W., Jiang, Z., Li, M., Jin, H., Cui, G., Chen, P., *et al.*
922 (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine
923 (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind,
924 placebo-controlled, phase 1/2 clinical trial. *The Lancet. Infectious diseases* *21*, 803-812.

925 Wu, Z., Zhang, Z., Lei, Z., and Lei, P. (2019). CD14: Biology and role in the pathogenesis of
926 disease. *Cytokine & growth factor reviews* *48*, 24-31.

927 Xia, X., Wang, M., Li, J., Chen, Q., Jin, H., Liang, X., and Wang, L. (2021). Identification of
928 potential genes associated with immune cell infiltration in atherosclerosis. *Mathematical*
929 *biosciences and engineering* : MBE *18*, 2230-2242.

930 Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., *et al.*
931 (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in

932 healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2

933 clinical trial. The Lancet. Infectious diseases 21, 181-192.

934

935 **Figures**

936 **Figure 1. CoronaVac Study Overview and Antibody Expression.**

937 (A) Study overview. Fifty subjects were recruited. Different samples were taken at NJ
938 (baseline, day 0), FJ (about 21 days after first immunization) and SJ (about 14 days
939 after second immunization). (B) Representative SARS-CoV-2 S-specific IgG and IgM
940 in each subject. (C) Average levels of SARS-CoV-2 S-specific IgG and IgM in each
941 group. Comparison of response between different time points was done using paired t
942 test. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

943

944 **Figure 2. Enrichment and Distribution of Immune Related Proteins.**

945 (A) GO analysis of the total DEPs from FJ vs NJ and SJ vs NJ. (B) The KEGG
946 pathway enrichment analysis of the total DEPs from FJ vs NJ and SJ vs NJ. (C)
947 Heatmap of selected proteins from three enriched pathways: complement response,
948 humoral immune response, and other immune associated-pathways. (D) The
949 expression level comparison of humoral immune related proteins with significant
950 differences. Statistical significance was determined by paired two-sided Welch's t test.
951 * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$. (E) Network of GO modules related to the
952 immune response defined by clusterProfiler v0.1.4. (F) Interaction diagram of
953 proteins involved in the humoral immune response, regulation of humoral immune
954 response, complement activation, and regulation of complement activation.

955

956 **Figure 3. Enrichment and Distribution of Immune Related Metabolites.**

957 (A) Venn diagram showing the number of differentially expressed metabolites
958 (DEMs). (B) The KEGG pathway enrichment analysis of the total DEMs from FJ vs
959 NJ and SJ vs NJ. (C) Heatmap of the DEMs associated with three enriched pathways:
960 complement system, humoral immune response, and other immune
961 associated-pathways.

962

963 **Figure 4. Changes in Amino Acid Levels, Carbohydrate Levels, and Their**

964 **Metabolic Pathways After Vaccination.**

965 (A) Circulating levels of TCA metabolites in plasma. Serum levels of metabolites
966 involved in the TCA cycle were significantly changed when comparing vaccination
967 samples with baseline samples. (B) Significant changes were seen in the levels of
968 some intermediates of the arginine and proline metabolism pathways in plasma of
969 vaccine-immunized samples. (C) Significant changes were observed in the levels of
970 some intermediates of the phenylalanine metabolism pathways in plasma of
971 vaccine-immunized samples. (D) Significant changes were observed in the levels of
972 metabolites involved in glycine, serine and threonine metabolism pathways after
973 vaccination. Statistical significance was determined by paired two-sided Welch's t test.
974 * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

975

976 **Figure 5. MRN analysis of Metabolomics, Proteomics, and Antibodies.**

977 (A) MRN consists of correlation networks using data from antibody, proteomics, and
978 metabolomics. Each node is a child network of one data type. The links between
979 nodes were established by weight. (B) The top pathways for metabolite networks
980 correlated with IgG levels at FJ time point. (C) The top pathways for metabolite
981 networks correlated with IgG levels at SJ time point. (D) Connections between IgG,
982 humoral response associated network and metabolite networks at FJ time point are
983 shown. (E) Connections between IgG, humoral response associated network and
984 metabolite networks at SJ time point are shown.

985

986 **Figure 6. Comparison of DEPs and their enriched pathways in severe COVID-19 987 infection, non-severe COVID-19 infection, FJ and SJ group.**

988 (A) Venn diagram showing the number of differentially expressed proteins in severe
989 COVID-19, non-severe COVID-19, FJ and SJ. (B) GO analysis of DEPs from severe
990 COVID-19 vs healthy. (C) KEGG analysis of DEPs from non-severe COVID-19 vs
991 healthy. (D) Heatmap of the top 20 GO terms enriched from DEPs in severe
992 COVID-19 vs healthy, non-severe COVID-19 vs healthy, FJ vs NJ and SJ vs NJ. (E)
993 Radar map of the top 20 GO terms enriched from DEPs in severe COVID-19 vs

994 healthy, non-severe COVID-19 vs healthy, FJ vs NJ and SJ vs NJ, respectively.
 995 -Log10 p values of GO terms were used to make the radar map. (F) Heatmap of DEPs
 996 from vaccination and infection that were related to platelet degranulation macrophage
 997 function, complement response, humoral immune response and other
 998 immune-associated pathway.

999

1000 **Figure 7. Comparison of DEMs and their enriched pathways in severe**
 1001 **COVID-19 infection, non-severe COVID-19 infection, FJ and SJ group.**

1002 (A) Venn diagram showing the number of differentially expressed metabolites in
 1003 severe COVID-19, non-severe COVID-19, FJ and SJ. (B) KEGG analysis of DEMs
 1004 from severe COVID-19 vs healthy. (C) KEGG analysis of DEMs from non-severe
 1005 COVID-19 vs healthy. (D) Heatmap of the top 20 KEGG terms enriched from DEMs
 1006 in severe COVID-19 vs healthy, non-severe COVID-19 vs healthy, FJ vs NJ and SJ vs
 1007 NJ. (E) Radar map of the top 20 KEGG terms enriched from DEMs in severe
 1008 COVID-19 vs healthy, non-severe COVID-19 vs healthy, FJ vs NJ and SJ vs NJ,
 1009 respectively. -Log10 p values of GO terms were used to make the radar map. (F)
 1010 Heatmap of the common metabolites shared between CoronaVac immunization and
 1011 infection.

A **Plasma signatures** **Multifactorial response network** **Comparison of vaccination and infection** **B** **C**

A

FJ/NJ

SJ/NJ

243

499

139

B

C